RDY — DR REDDYS LABORATORIES LTD

NYSE · Health Care · Pharmaceuticals · CIK 1135951 · India
Last close
$11.79
Market Cap
$9.82B
52W High
$15.67
52W Low
$11.36
ADV30
2,951,325
Next earnings
2026-10-22
Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company North America, Europe, India, Russia, and internationally. The company operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segment. Its Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids with the customer requirements. Its Others segment engages in developing therapies in the fields of oncology and inflammation; and research, development, and commercialization of differentiated formulations. The company offers its products for various therapeutic categories, including gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology, vaccines, vitamins and minerals, and pain management. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGrossProfit OpIncomeNetIncomeAssets CashLiabilities
Jun 2026 80,705,000,000 37,540,000,000 3,033,000,000 4,435,000,000 575,305,000,000 11,204,000,000 188,570,000,000
Mar 2026 75,162,000,000 43,035,000,000 829,000,000 2,209,000,000 579,346,000,000 15,368,000,000 198,889,000,000
Dec 2025 87,268,000,000 46,806,000,000 14,330,000,000 12,098,000,000 562,899,000,000 18,657,000,000 187,143,000,000
Sep 2025 88,051,000,000 48,140,000,000 17,867,000,000 14,372,000,000 542,005,000,000 9,906,000,000 179,923,000,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$63,106,000,000
Investing CF
$-52,327,000,000
Financing CF
$-6,119,000,000
CapEx
$-38,848,000,000
Dividends Paid
$-6,659,000,000
Buybacks
EPS Diluted TTM
$67.89
As of
2026-05-10

Balance + Analyst (yfinance extras)

Retained Earnings
$349,783,000,000
Inventory
$79,009,000,000
Receivables
$124,269,000,000
ST Investments
$63,932,000,000
EBIT TTM
$76,217,000,000
Pretax Income TTM
$72,880,000,000
Interest Exp TTM
$3,337,000,000
Analysts
5

Yahoo Snapshot (yfinance, live)

Total Revenue
$331,186,012,160
EBITDA
$54,671,998,976
Free Cash Flow
$-3,909,625,088
Enterprise Value
$52,689,563,648
Total Cash
$81,426,997,248
Total Debt
$71,951,998,976
Shares Out
832,726,158
Trailing EPS
$0.41
Book Value
$0.80
ROE
8.8%
ROA
4.0%
Div Yield
0.71%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOpIncome NetIncomeAssetsLiabilities EquityOCF
Mar 2026 335,933,000,000 50,123,000,000 42,850,000,000 579,346,000,000 198,889,000,000 56,755,000,000
Mar 2025 325,535,000,000 72,014,000,000 56,544,000,000 492,989,000,000 155,823,000,000 46,428,000,000
Mar 2024 279,164,000,000 65,308,000,000 55,684,000,000 387,518,000,000 106,968,000,000 45,433,000,000
Mar 2023 245,879,000,000 59,054,000,000 45,067,000,000 321,854,000,000 90,863,000,000 58,875,000,000

TTM Snapshot

Revenues TTM
NetIncome TTM
OpCashFlow TTM
Assets (Latest)
Forward EPS
$0.64

Max Pain — expiry 2026-09-18 (volume-derived — Yahoo OI feed degraded)

max pain strike: $15.00 · spot: $11.79 · call volume: 19 · put volume: 112
Expected Move to 2026-09-18: ±$1.20 (10.14%) — implied range $10.59$12.98 · ATM straddle on $12.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
CORT CORCEPT THERAPEUTICS INC $10.24B $95.36
IONS IONIS PHARMACEUTICALS INC $9.35B $56.55
NUVL Nuvalent, Inc. $9.12B $123.96
SMMT Summit Therapeutics Inc. $10.60B $13.66
PRAX Praxis Precision Medicines, Inc. $9.07B $325.30

News headlines (Yahoo Finance, 1h cache)

Dr. Reddy's Q1 Earnings and Revenues Miss Estimates, Stock Down
2026-07-23 14:38 · Yahoo
Asian Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading
2026-07-23 14:33 · Yahoo
Dr. Reddy's Laboratories Q1 Earnings Call Highlights
2026-07-22 17:06 · Yahoo
Asian Equities Traded in the US as American Depositary Receipts Decline in Wednesday Trading
2026-07-22 14:44 · Yahoo
Asian Equities Traded in the US as American Depositary Receipts Rise Sharply in Tuesday Trading
2026-07-21 14:42 · Yahoo
Asian Equities Traded in the US as American Depositary Receipts Rise in Monday Trading
2026-07-20 14:38 · Yahoo
Dr. Reddy's Laboratories Flags Semaglutide Supply Delay, Says No Recall Risk
2026-07-12 21:02 · Yahoo
Asian Equities Traded in the US as American Depositary Receipts Rise in Friday Trading
2026-07-10 14:27 · Yahoo
Asian Equities Traded in the US as American Depositary Receipts Advance in Thursday Trading
2026-07-09 14:35 · Yahoo
Asian Equities Traded in the US as American Depositary Receipts Drop Sharply in Tuesday Trading
2026-07-07 14:40 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.